Trial
NCT02058108
Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Chronic Hepatitis B
Intervention
Telbivudine
Why stopped
Study terminated on the recommendation of an independent Data Monitoring Committee (DMC) subsequent to an interim efficacy analysis for futility.\]
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-09-10